Get started
Author

Hidetoshi Irifune

TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in acute myeloid leukemia
2023 · Teppei Sakoda, Yoshikane Kikushige, et al. · Blood Advances · 47
PDF
Human acute leukemia uses branched-chain amino acid catabolism to maintain stemness through regulating PRC2 function
2022 · Yoshikane Kikushige, Toshihiro Miyamoto, et al. · Blood Advances · 34
PDF
Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia
2020 · Taro Tochigi, Toshihiro Miyamoto, et al. · Blood · 19
PDF
TIM ‐3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation
2024 · Teppei Sakoda, Yoshikane Kikushige, et al. · Cancer Science · 12
GPAM mediated lysophosphatidic acid synthesis regulates mitochondrial dynamics in acute myeloid leukemia
2023 · Hidetoshi Irifune, Yu Kochi, et al. · Cancer Science · 9
PDF
Evaluation of TIM-3-Positive LSCs Post Allo-SCT Is a Highly Sensitive Strategy to Predict AML Relapses
2019 · Teppei Sakoda, Yoshikane Kikushige, et al. · Blood · 5
Engraftment syndrome after PD-1 blockade in classical Hodgkin lymphoma treated by autologous stem cell transplantation
2025 · Huiyeon Choi, Takuji Yamauchi, et al. · International Journal of Hematology · 2
PDF
[Identification of GPAT1-dependent mitochondrial metabolism as a novel therapeutic target for AML].
2022 · Hidetoshi Irifune · PubMed · 2
Evaluation of TIM-3+ LSCs Is a Highly Sensitive MRD Monitoring Strategy to Predict AML Relapse after Allogenic Stem Cell Transplantation
2018 · Masayasu Hayashi, Teppei Sakoda, et al. · Blood · 2
Neutrophil Engraftment Timing after Single-Unit Cord Blood Transplantation as a Prognostic Marker of Transplant Outcomes Influenced by GVHD Prophylaxis: A nationwide, retrospective study by the Japanese Society for Transplantation and Cellular Therapy
2026 · Takashi Oyama, Mitsuhiro Yuasa, et al. · Transplantation and Cellular Therapy
Sequential emergence of FLT3-ITD and BCR::ABL1 during disease progression in relapsed acute myeloid leukemia
2026 · Hidetoshi Irifune, Yuichiro Semba, et al. · Annals of Hematology
Identification of GPAT1 As a Novel Therapeutic Target for Acute Leukemia By Inhibiting Leukemia Specific Metabolism
2019 · Hidetoshi Irifune, Yu Kochi, et al. · Blood
Identification of GPAT1 as a novel therapeutic target for AML by inhibiting AML-specific metabolism
2019 · Hidetoshi Irifune · The Japanese Society of Hematology
Evaluation of TIM-3+ AML stem cells should be significant to predict early relapses after allo-SCT
2018 · Hidetoshi Irifune · The Japanese Society of Hematology
Works count: 14
Citation count: 132
H-index: 5
I10-index: 4
Year
Topic
Type